We investigated the long-term effects of human hepatocyte growth factor (HGF) gene therapy in a rat myocardial infarct model. Treatment adenovirus coexpressing the HGF therapeutic gene and the human sodium/iodide symporter (NIS) reporter gene or control adenovirus expressing the NIS gene alone were injected directly into the infarct border zone immediately after permanent coronary ligation in rats (n ¼ 6 each). A uniform disease state was confirmed in the acute phase in terms of impaired left ventricular (LV) function by cine magnetic resonance imaging (MRI), large infarct extent by 99m Tc-tetrofosmin single-photon emission computed tomography (SPECT) and successful gene transfer and expression by 99m TcO 4 À SPECT. After a 10-week follow-up, repeated cine MRI demonstrated no significant difference in the LV ejection fraction between the time points or groups, but a significantly increased end-diastolic volume from the acute to the chronic phase without a significant difference between the groups. Capillary density was significantly higher in the treatment group, whereas arteriole density remained unchanged. Two-photon excitation fluorescence microscopy revealed extremely thin capillaries (2--5 mm), and their irregular networks increased in the infarct border zone of the treated myocardium. Our results indicated that single HGF gene therapy alone induced an immature and irregular microvasculature.
INTRODUCTION
Cardiac angiogenic gene therapy aims at facilitating neovascularization to augment blood flow in an ischemic myocardium by transfer of genes for angiogenic factors, such as vascular endothelial growth factor and fibroblast growth factor, and several clinical trials have been conducted in this regard. 1, 2 Hepatocyte growth factor (HGF) is another candidate therapeutic gene with potent angiogenic, antiapoptotic and antifibrotic activities. 3, 4 However, to date, no clinical trial has demonstrated the beneficial effects of HGF gene therapy in ischemic heart diseases despite several encouraging results in animal studies. 5--17 Such clinical trials may have encountered difficulties such as individual differences in disease state (for example, infarct extent and left ventricular (LV) function), individual variability in the efficiency of therapeutic gene delivery and expression and confounding effects of concomitant revascularization therapy. 2 Moreover, animal studies faced difficulties in assessing angiogenesis in vivo. In addition, most animal studies reported the therapeutic effects of HGF gene therapy for relatively short periods within a month. 5--7,9--17 In this study, we therefore investigated the long-term effects of HGF gene therapy in a rat myocardial infarct model using multimodal methods. First, we constructed a Treatment adenovirus coexpressing the HGF therapeutic gene and the human sodium/iodide symporter (NIS) reporter gene (Ad-CMV-HGF-CMV-NIS) and a Control adenovirus expressing the NIS gene alone (Ad-CMV-NIS), and obtained proof-of-principle data for gene expression imaging using single-photon emission computed tomography (SPECT) and these constructs in vitro before animal experiments.
We used a rat myocardial infarct model and immediately injected the treatment or control adenovirus directly into the myocardium of the infarct border zone. In the acute phase, we ensured a uniform disease state in the animal groups by cine magnetic resonance imaging (MRI) on day 1, 99m TcO 4 À SPECT on day 2 and 99m Tc-tetrofosmin (TF) SPECT on day 4. After a 10-week follow-up, we assessed changes in LV function and infarct extent using repeated cine MRI and 99m Tc-TF SPECT. Finally, we assessed the therapeutic effects on angiogenesis in the chronic phase (week 10) using two-photon excitation fluorescence microscopy (TPEFM) for the visualization of the three-dimensional (3D) microvasculature and using immunohistochemistry for the quantitative assessment of capillary and arteriole density.
RESULTS
In vitro proof-of-principle data for gene expression imaging On western blots from Ad-CMV-HGF-CMV-NIS-transfected H9c2 cardiomyoblasts, both NIS and HGF proteins were recognized at B97 and 103 kDa, respectively, depending on the virus titer, whereas only the NIS protein was observed on western blots from Ad-CMV-NIS-transfected cells (Figure 1a) . The wide band for the NIS protein was probably attributable to the preparation method from the membrane fraction. 18 The 99m TcO 4 À uptake assay demonstrated that radiotracer uptake in the Ad-CMV-HGF-CMV-NIS-and Ad-CMV-NIS-transfected cells markedly increases (up to 582-fold) with an increase in the virus titer, and that 99m TcO 4 À uptake was completely inhibited by the addition of potassium perchlorate (Figure 1b) . Over the range of virus titers tested, high correlations existed between gene expression levels and 99m TcO 4 À uptake levels (Figures 1c and d) . Although a plateau of 99m TcO 4 À uptake levels to HGF protein levels was observed (Figure 1d ), similar plateau phenomena have been reported in other radionuclide reporter gene imaging. 19 Assurance of uniform randomization of disease state and successful transgene expression Each animal underwent all of cine MRI and 99m TcO 4 À and 99m Tc-TF SPECT in the acute phase. As a result, 5 rats (4 with no or small infarct extent, 3 of them with normal LV function and 1 with insufficient local gene expression; 3 from treatment group and 2 from control group) were excluded to ensure uniform randomization and killed without follow-up. Subsequently, 12 (6 treatment and 6 control) rats showing large infarct extent, impaired LV function and successful local gene expression to similar degrees were enrolled in the study. No significant difference was observed between the treatment and control groups in the LV ejection fraction (LVEF) or end-diastolic volume (EDV), as assessed by cine MRI on day 1 (Table 1) . A large extent of perfusion defect was similarly observed in the LV anterolateral wall in all study rats in both groups using 99m Tc-TF SPECT on day 4. Transgene expression was constantly confirmed as regional 99m TcO 4 À accumulation in the border zone of the perfusion defect in all study rats by 99m TcO 4 À SPECT on day 2. The percentage of injected dose (%ID) of 99m TcO 4 À was 0.27 ± 0.04% in the treatment group and 0.18±0.03% in the control group in proportion to the injected virus titers (Po0.01). Figure 2 shows SPECT/CT images with 99m TcO 4 À of gene expression and with 99m Tc-TF of myocardial perfusion in a representative rat.
Assessment of changes in LV function and infarct extent Table 1 summarizes the changes in the parameters of LV function measured by cine MRI from the acute (day 1) to the chronic phase (week 10). No significant difference was observed in the functional parameters of LVEF and EDV between the two groups, except that EDV alone increased over time, indicating ventricular remodeling in all groups. No rat showed a significant change in infarct extent on 99m Tc-TF SPECT images from the acute to the chronic phase ( Figure 2 ).
Visualization of the 3D microvasculature TPEFM clearly visualized the 3D microvasculature. Extremely thin capillaries (2--5 mm, diameter), which had been presumably induced by HGF gene therapy, were observed exclusively in the infarct border zone of the myocardium in the treatment group, but not in the control group (data not shown) or in the intact regions of another coronary territory in the treatment group ( Figure 3 ). In addition, microvessels in the intact regions ran and branched in an orderly manner along the muscle fascicles of the myocardium, which is considered to coordinate the proper delivery of blood cells in accordance with myocardial contraction. 20 In contrast, microvessels in the treated regions were irregularly connected to each other independent of myocardial orientation, suggesting a disorganized microvascular network. À uptake levels. These findings indicated that capillaries newly induced by HGF gene therapy remained immature and irregular even in the chronic phase, which might hamper regulated microcirculation.
Histological confirmation of myocardial infarction
The uniform state of myocardial infarction in both groups was also confirmed in the chronic phase ex vivo by histological examination with Masson's trichrome staining. All hearts in both groups were similar in appearance in terms of the size of the LV cavity, thinning of the infarct region and distribution of fibrotic lesions. Quantitative parameters of the infarct extent and the border zone wall thickness did not differ between the two groups ( Figure 4 ).
Immunohistochemical assessment of angiogenesis Capillary density was significantly increased in the border zone of the myocardium in the treatment group compared with the control group (P ¼ 0.006), whereas the arteriole density was not ( Figure 5 ).
DISCUSSION
A major characteristic of the field of cardiac angiogenic gene therapy has been the disappointing fact that whereas preclinical trials as well as all published clinical trials without controls have yielded positive results, none of the randomized controlled trials have shown convincing and clinically relevant results. It is likely that overinterpretation have been made in many preclinical studies, and this has prompted clinical testing of factors and approaches with minor biological relevance and effects. 22 In the current study, we (1) reduced the sampling bias by ensuring uniform randomization of the disease state and the successful transgene expression, (2) precluded the transient antiapoptotic and antifibrotic effects of HGF by assessing the therapeutic effects at 10 weeks after the gene transfer when the gene expression had ceased and (3) evaluated 3D structure of the neoformed microvessels by TPEFM more directly and persuasively than by capillary density, all of which contributed toward avoiding such overinterpretation. Consequently, our results indicated that single HGF gene therapy alone induces an immature and irregular microvasculature. Despite all 13 previous animal studies on sole HGF gene therapy found in a literature search of the PubMed database reporting positive conclusions, 5--17 we for the first time reported negative results on the angiogenic effects and less prominent results on the LV functional recovery in this study.
A unique aspect of the present study was the use of NIS reporter gene imaging to confirm the technical success of transfer and expression of the HGF gene. Reporter genes for radionuclide imaging, such as SPECT and positron emission tomography, generally have the advantage of offering tomographic and quantitative information over those for fluorescent or bioluminescent imaging. In particular, NIS has additional advantages over other radionuclide reporter genes in that 99m TcO 4 À and various radioactive iodides for SPECT ( 123 I) and positron emission tomography ( 124 I) are readily available as its reporter probe, avoiding problems regarding tracer synthesis, labeling stability and metabolites. 2 Among the 13 articles reviewed, all 11 studies that examined the angiogenic effects of the gene therapy provisionally concluded that treatment with the HGF gene led to angiogenesis on the basis of the findings of increased microvessel density determined by immunohistochemistry analyses. 5,6,8--11,13--17 However, such 2D analysis of post-mortem tissue sections provides information on neither the 3D vascular network nor the geometry. Our present data support the previous findings of an increase in capillary density after HGF gene therapy, and provide at the same time the convincing evidence for capillary immaturity and the rabbit hindlimb ischemia model. 23 Moreover, repeated, but not single, vascular endothelial growth factor (VEGF) gene transfer has been shown to result in long-term stability of the neoformed microvessels. 24 Different as the therapeutic gene and the target organ are, given the transient nature of gene expression, instability and partial regression of the neovascular network could have occurred. Further studies are needed to clarify it using a technique for repetitive imaging of angiogenesis such as positron emission tomography imaging targeting aVb3 integrin. 25 In ischemic heart diseases, recovery of LV function after HGF gene therapy alone is also controversial. Among the 13 articles mentioned above, 11 studies reported some functional recovery after the therapy.
5--8,10--13,15--17 Only Miyagawa et al. 26 reported that LV function was not improved in myocardial infarction rats treated with the HGF gene alone; however, it improved in myocardial infarction rats treated with a combination of the HGF gene and neonatal cardiomyocytes. Some investigators attempted to explain this discrepancy to be a result of too late initiation of the therapy in the study of Miyagawa et al. 26 because at 2 weeks after myocardial infarction, the infarct had already begun to change into a scar, although this possible explanation does not seem to match the positive observation in their HGF gene and stem cell combination group. 4, 7 In the present study, we did not find statistically significant differences in LVEF and EDV between the treatment and control groups despite HGF gene therapy being initiated immediately after coronary ligation.
Indeed, rather than the timing of therapy initiation, a major difference seems to exist in the study protocol between the inconsistent study groups, specifically, in terms of the follow-up period. In the previous studies, 5--8,10--13,15--17 the positive functional recovery was observed at 2--6 weeks after HGF gene transfer, whereas we repeated the measurement of LV function at a relatively long-term time point of 10 weeks after the gene transfer. Although we could not perform cine MRI at three different time points because of its limited availability, Miyagawa et al. 26 measured LVEF and percentage fractional shortening by echocardiography 3 times up to 8 weeks and, interestingly, reported slight improvement in the functional parameters at 4 weeks and their return to baseline levels at 8 weeks in the HGFtreated group. Typically, transgene expression levels after adenovirus-mediated transfer are transient, lasting only 4--6 weeks. 27, 28 This raises the possibility that the functional recovery in the study of Miyagawa et al. 26 and our study became less prominent late after gene transfer, whereas that in other positive studies was prominent early after gene transfer, probably because the antiapoptotic and antifibrotic effects of HGF gene therapy on ventricular remodeling and dysfunction may be transient and be lost after HGF expression ceases.
This study has some limitations. First, the number of animals in our study (six per group) was the minimum number for statistical analysis. Indeed, increased number of animals might have resulted in a statistically significant difference in the analyses of functional parameters; however, the number of animals in our study was not necessarily smaller than that in the 11 previous studies showing functional recovery (6.9±2.1 per group; range 5--15 per group).
5--8,10--13,15-- 17 We ensured uniform randomization of the disease state and the successful transgene expression to reduce sampling bias, which made our research design rather sensitive to statistical differences than the previous studies. Nevertheless, only we did not find a statistically significant difference probably because the time point of the functional measurements was different from the previous studies. Yet, we believe our results worth enough to raise the alarm to possible overinterpretation of those previous studies. Second, we used a myocardial infarction model despite the main clinical target of angiogenic gene therapy being ischemic but viable myocardium. However, in this study, we had to choose rats in order to use TPEFM; production of a rat myocardial ischemia model is considerably difficult. Therefore, the angiogenic and cardioprotective effects of HGF gene therapy in the late phase of myocardial ischemia remain unclear. Further long-term studies of HGF gene therapy in a myocardial ischemia model in large animals with ameroid constrictors may be required for this purpose.
Finally, there are a few key issues that need to be addressed for future developments in the field of gene therapy and therapeutic angiogenesis. One likely explanation for the lack of decisive evidence of the therapeutic effects is that therapeutic protein concentration in target tissue has not reached sufficient levels and/or has not persisted long enough to complete angiogenesis. 22 To resolve this problem, development of a novel vector that enables more efficient gene transfer and/or longer-term gene expression and of a novel method to regulate gene expression is expected. Taking advantage of a 'master gene', the expression of which activates various other genes in an angiogenic cascade, may induce more physiological angiogenesis. Otherwise, using multiple therapeutic genes carried together (a 'gene cocktail') may lead to broader angiogenesis. Furthermore, recruiting progenitor cells or stem cells in combination with angiogenic gene therapy may exert synergistic therapeutic effects, hopefully leading to reduction in the dose and risk of the therapeutic gene. 2 
MATERIALS AND METHODS

Cell lines
Human embryonic kidney 293A (HEK293A; Invitrogen, Carlsbad, CA, USA) and rat embryonic cardiomyoblasts H9c2 (American Type Culture Collection, Manassas, VA, USA) cells were cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich, St Louis, MO, USA) with fetal bovine serum (10%), Lglutamine (2 mM), penicillin (100 IU ml --1 ) and streptomycin (50 mg ml --1 ).
Adenovirus production
A replication-defective recombinant adenovirus vector was constructed using the ViraPower Adenoviral Expression System (Invitrogen) according to the manufacturer's protocol. This vector (Ad-CMV-HGF-CMV-NIS) contained dual constitutive cytomegalovirus (CMV) promoters to proportionally drive the human HGF gene (NM_001530; OriGene Technologies, Rockville, MD, USA) and the human NIS gene (NM_000453) obtained by the PCR. 29 Similarly, a negative control adenovirus vector containing only the NIS gene driven by a CMV promoter (Ad-CMV-NIS) was also constructed. The adenoviruses were propagated in HEK293A cells, purified using the Adeno-X Maxi purification Kit (Clontech, Palo Alto, CA, USA) and titered using the Adeno-X Rapid Titer Kit (Clontech). The highest virus titer achieved was 9 Â 10 9 infectious units (IFU) ml --1 for Ad-CMV-HGF-CMV-NIS and 5 Â 10 9 IFU ml --1 for Ad-CMV-NIS. Virus stocks were all stored in a deep freezer at À80 1C.
Western blot analysis
HGF and NIS protein expression in Ad-CMV-HGF-CMV-NIS-or Ad-CMV-NIS-transfected H9c2 cells was detected by western blot analysis. 18 Transfection was performed with Ad-CMV-HGF-CMV-NIS or Ad-CMV-NIS at multiplicities of infection of 0, 1, 5, 10, 20, 50 and 100. After 48 h, cell lysates for the HGF protein were prepared from H9c2 cells, and its membrane protein fraction was extracted for the NIS protein. 30 Goat polyclonal IgG anti-human HGF antibody (AF-294-NA; R&D Systems, Minneapolis, MN, USA) and mouse monoclonal anti-human NIS antibody (clone FP5A; Lab Vision, Fremont, CA, USA) were used to quantitatively determine HGF and NIS protein levels, respectively, on the basis of optical density measurements. The HGF and NIS protein levels were normalized to a-tubulin protein levels.
The
99m TcO 4 À uptake assay
The NIS protein function was tested by performing the 99m TcO 4 À uptake assay.
31. H9c2 cells transfected with various titers of virus were prepared as described above. The 99m TcO 4 À uptake levels in the transfected cells were expressed as a fold increase compared with those in the control cells without transfection. All experiments were performed in triplicate and repeated 4 times independently.
Animal surgery
In this study, 10-week-old male Wistar rats (231±19 g, Japan SLC, Hamamatsu, Japan) were used. The rats were intubated for mechanical ventilation and deeply anesthetized with 1--2% isoflurane (Mylan Japan, Tokyo, Japan). A left thoracotomy was performed through the fourth intercostal space, and myocardial infarction was induced by ligation of the left anterior descending coronary artery 2--3 mm from the tip of the left auricle using a 6-0 polypropylene suture. The infarction was visibly confirmed by blanching of the non-perfused area at the time of ligation. Immediately, Ad-CMV-HGF-CMV-NIS (1.8 Â 10 9 IFU) was injected directly into the myocardium of the infarct border zone in the treatment group, and Ad-CMV-NIS (1 Â 10 9 IFU) was similarly injected in the control group. A total volume of 200 ml was injected into three separate areas of the myocardium.
All Cine MRI for LV function Cine MRI was performed to assess LV function on day 1 and in week 10. MR images were obtained on a 7.0 T-MRI scanner (40-cm bore, Magnet: Kobelco and Jastec, Kobe, Japan; Console: Bruker Biospin, Ettlingen, Germany) with a volume coil for transmission (Bruker Biospin) and a 2-ch phased-array coil for reception (Rat heart coil; Rapid Biomedical, Rimpar, Germany). Rats were intubated for mechanical ventilation using a MRIcompatible rodent ventilator (MRI-1; CWE, Ardmore, PA, USA) and anesthetized with 1--1.5% isoflurane (Mylan Japan) in a prone position on an MRI-compatible cradle (Rapid Biomedical). The slice orientation of short-axis planes was carefully adjusted perpendicularly to the cardiac axis on a sagittal scout image. Incoherent gradient-echo fast low-angle shot sequence-based cardiac cine MRI (IntraGate; Bruker Biospin) was performed using respiratory and cardiac gating with the following parameters: TR ¼ 34. 32 Ten frame sets of 2D, multislice, short-axis cardiac images were obtained. Image reconstruction and analysis were performed using ParaVision (Bruker Biospin) and MRVision (MRVision, Winchester, MA, USA). The LV cavity was manually delineated on short-axis images because of the unclear automatic separation of the papillary muscles from the myocardial wall. 32 EDV and end-systolic volume (ESV) were measured, and ejection fraction (%) was calculated as (EDVÀESV)/EDV Â 100. À (Fujifilm RI Pharma, Tokyo, Japan) using a small-animal SPECT/CT system FX with a single-pinhole PH10 collimator (Gamma Medica-Ideas, Northridge, CA, USA) for high quantitative accuracy. At 30 min after intravenous injection of the radiotracer, 64 projections were obtained for 1 min per projection at the shortest radius of rotation (30 mm) in a 140 keV ± 10% energy window. Computed tomography images were acquired for anatomical orientation immediately after SPECT imaging. SPECT images were reconstructed using ordered subset expectation maximization (5 iterations, 4 subsets) without attenuation correction using the maker-supplied software. The reconstructed images were consistent with 80 Â 80 image matrixes, which achieved a spatial resolution of 0.8 mm. For quantitative analysis, a spherical region of interest (ROI) of 12 mm diameter was placed over the entire heart, and another spherical ROI of the same size for background activity was assigned to the right lung on the same slices. Transgene expression levels were estimated by measuring the radioactivity concentration in the cardiac ROI corrected for background activity in the second ROI and expressed as %ID.
The
99m Tc-TF SPECT/CT for infarct extent
Tc-TF SPECT/CT imaging of myocardial perfusion was performed on day 4 and in week 10. SPECT images were obtained with 222 MBq of 99m Tc-TF (Nihon Medi-Physics, Tokyo, Japan) using the same SPECT/CT system equipped with a 5-pinhole 5B10 collimator (Gamma Medica-Ideas) for high sensitivity. The imaging protocol and image reconstruction were the same as for 99m TcO 4 À SPECT/CT, except that the shortest radius of rotation was 40 mm when equipped with the 5B10 collimator. Infarct extent was visually assessed on reoriented images and a 3D display.
TPEFM for the 3D microvasculature TPEFM was performed in week 10. 33 Under anesthesia with 1--1.5% isoflurane (Mylan Japan), rats were perfused with a cocktail of 7% gelatin and 3 mM Texas red 7-kDa dextran conjugate (Invitrogen) in warm saline (60 ml, 35--40 1C) from the femoral vein at a rate of 1.7 ml min --1 . In total, 25 ml gelatin solution was perfused until cardiac arrest, whereas blood was washed out from the femoral artery to maintain body fluid balance. The heart was removed immediately after cardiac arrest and imaged using a two-photon microscope (Leica Microsystems, Wetzlar, Germany) at 900-nm excitation. The objective lens was a 20 Â water immersion lens (1.0 numerical aperture), and two channels of fluorescent signals were simultaneously obtained through a bandpass filter of 520/50 nm and 610/ 75 nm for imaging of green autofluorescence from the muscle fiber and blood vessel fixed with gelatin, respectively. The image size was 1024 Â 1024 pixels with a pixel resolution of 0.28 mm. A 3D structure image was obtained from the surface to a depth of 150 mm, with a z-step interval of 5 mm.
33
Histological analyses by tissue staining Hearts were excised immediately after TPEFM. Cardiac specimens were formalin fixed and sliced into 5-mm short-axis cross-sections using a standard microtome. The sections were stained with Masson's trichrome for cell necrosis and fibrosis. 34 Infarct extent (%) was calculated as infarct circumference divided by LV circumference Â 100 on a slice with the maximum infarct extent. The border zone wall thickness, which has been reported as a parameter of ventricular remodeling after myocardial infarction, 8, 10 was also measured at the center of the infarct border zone consisting of both normal and scar tissues on the same slice. Specimens were also immunostained with platelet/endothelial cell adhesion molecule-1 (sc-1506; Santa Cruz Biotechnology, Santa Cruz, CA, USA) using a goat ABC staining system (sc-2023; Santa Cruz Biotechnology) for capillaries and a-smooth muscle actin immunohistology kit (IMMH2; Sigma-Aldrich) for arterioles, according to the manufacturer's protocols. The number of capillaries and arterioles was counted in eight representative infarct border zone fields at magnifications of Â 100 and Â 40, respectively, and were semiquantitatively expressed as density (per mm 2 ).
Statistical analysis
Data are presented as means ± s.d. Two-way repeated measure analysis of variance with post hoc Bonferroni tests was used for changes in LVEF and EDV from the acute to the chronic phase in the treatment and control groups. Unpaired Student's t-test was used to compare mean values between the two groups. Least squares fitting of a linear or nonlinear (onephase exponential) equation was used for correlation analyses. All statistical analyses were performed using Prism 5 for Mac OS X (GraphPad Software, La Jolla, CA, USA). The P-values of o0.05 were considered statistically significant.
